Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Author(s): Hope S. Rugo, MD¹; Aditya Bardia, MD, MPH²; Frederik Marmé, MD, PhD³; Javier Cortes, MD, PhD^4,5; Peter Schmid, MD, PhD⁶; Delphine Loirat, MD, PhD⁷; Olivier Trédan, MD, PhD⁸; Eva Ciruelos, MD, PhD⁹; Florence Dalenc, MD, PhD¹⁰; Patricia Gómez Pardo, MD¹¹; Komal L. Jhaveri, MD¹²; Rosemary Delaney, MPH¹³; Olivia Fu, MD¹⁴; Lanjia Lin, PhD¹⁵; Wendy Verret, PhD¹³; and Sara M. Tolaney, MD, MPH¹⁶

Source: DOI: 10.1200/JCO.22.01002 Journal of Clinical Oncology 40, no. 29 (October 10, 2022) 3365-3376

Dr. Maen Hussein's Thoughts

Another option for HR+ /HER-2 negative pts who failed hormonal therapies, caution to toxicity though esp neutropenia and diarrhea, no OS data yet, will be interesting to know if it worth the adverse events at this stage of disease.

ABSTRACT

PURPOSE

Hormone receptor–positive (HR+) human epidermal growth factor receptor 2–negative (HER2–) endocrine-resistant metastatic breast cancer is treated with sequential single-agent chemotherapy with poor outcomes. Sacituzumab govitecan (SG) is a first-in-class antibody-drug conjugate with an SN-38 payload targeting trophoblast cell-surface antigen 2, an epithelial antigen expressed in breast cancer.

METHODS

In this global, randomized, phase III study, SG was compared with physician’s choice chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) in endocrine-resistant, chemotherapy-treated HR+/HER2– locally recurrent inoperable or metastatic breast cancer. The primary end point was progression-free survival (PFS) by blinded independent central review.

RESULTS

Patients were randomly assigned to receive SG (n = 272) or chemotherapy (n = 271). The median age was 56 years, 95% had visceral metastases, and 99% had a prior cyclin-dependent kinase 4/6 inhibitor, with three median lines of chemotherapy for advanced disease. Primary end point was met with a 34% reduction in risk of progression or death (hazard ratio, 0.66 [95% CI, 0.53 to 0.83; P = .0003]). The median PFS was 5.5 months (95% CI, 4.2 to 7.0) with SG and 4.0 months (95% CI, 3.1 to 4.4) with chemotherapy; the PFS at 6 and 12 months was 46% (95% CI, 39 to 53) v 30% (95% CI, 24 to 37) and 21% (95% CI, 15 to 28) v 7% (95% CI, 3 to 14), respectively. Median overall survival (first planned interim analysis) was not yet mature (hazard ratio, 0.84; P = .14). Key grade ≥ 3 treatment-related adverse events (SG v chemotherapy) were neutropenia (51% v 38%) and diarrhea (9% v 1%).

CONCLUSION

SG demonstrated statistically significant PFS benefit over chemotherapy, with a manageable safety profile in patients with heavily pretreated, endocrine-resistant HR+/HER2– advanced breast cancer and limited treatment options.

Author Affiliations

¹Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; ²Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; ³Medical Faculty Mannheim, Heidelberg University, University Hospital Mannheim, Heidelberg, Germany; ⁴Medical Oncology Department, International Breast Cancer Center, Pangaea Oncology, Quironsalud Group, Madrid and Barcelona, Spain; ⁵Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid, Spain; ⁶Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; ⁷Medical Oncology Department and D3i, Institut Curie, Paris, France; ⁸Medical Oncology Department, Centre Léon Bérard, Lyon, France; ⁹Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain; ¹⁰Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; ¹¹Hospital Universitari Vall D’Hebron, Barcelona, Spain; ¹²Memorial Sloan-Kettering Cancer Center, New York, NY; ¹³Department of Clinical Development, Gilead Sciences Inc, Foster City, CA; ¹⁴Department of Global Patient Safety, Gilead Sciences Inc, Foster City, CA; ¹⁵Department of Biostatistics, Gilead Sciences Inc, Foster City, CA; ¹⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis

Among 1,545 women included with a median follow-up of 9.4 years in postmenopausal women, breast cancer events occurred in 40 of 335 receiving low-dose tamoxifen versus 93 of 401 controls HR, 0.51, with a 10-year absolute reduction of 11.2%. Among premenopausal women, no significant reduction was observed dose was 5mg daily of 10mg every other day in ductal carcinoma in situ (DCIS) and high-risk pts. Less is as good.

Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial

644 patients who are triple-negative breast cancer (TNBC) not candidates for immunotherapy were randomly assigned to receive Dato-DXd (n = 323) or chemotherapy (n = 321). Median progression-free survival (PFS) was 10.8 months with Dato-DXd and 5.6 months with chemotherapy. Median overall survival (OS) was 23.7 months and 18.7 months with Dato-DXd and chemotherapy, respectively HR 0.79; P = 0.029]. Treatment-related adverse events (TRAEs) of grade ≥3 were reported in 105 (33%) and 89 (29%) patients who received Dato-DXd and chemotherapy, respectively, they were more treatment discontinuation in the chemotherapy arm secondary to treatment related adverse events in 14 (4%) and 23 (7%) patients. There were no treatment-related deaths in either arm. New standard of care? Recall this is on patients not eligible for immunotherapy.

Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1

Less radiation (40Gy vs 50 Gy) was non inferior in preventing locoregional recurrence and distant mets, also lymphedema rates were not worse. Would love feedback from our rad onc, but it seems less is as good.

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer

Progression-free survival (PFS) was statistically significantly improved with addition of tucatinib versus placebo 24.9 v 16.3 months regardless of the presence/absence of BM or hormone receptor status.

Role of neoadjuvant versus adjuvant chemotherapy, dose density, and treatment schedule in biologically high-risk HR+/HER2- breast cancer: A pooled analysis of the WSG ADAPT-HR+/HER2- and PlanB trials.

1467 pts with RS > 25 and 551 with clinically (neoadjuvant cohort in ADAPT-HR+/HER2-) or pathologically N2, (longer) docetaxel-based CTx showed better distant, invasive disease-free survival in N2-3 pts patients with RS ≤25, OS was also shown in pts with RS>25 anthracycline regimens did not show a significant survival difference in high-risk HR+/HER2 whether used in neoadjuvant or adjuvant setting. So may be no anthracycline for HR+ve pts who are high risk disease.